Abstract
The liver is a common site for metastatic tumors, so differentiation of primary from metastatic lesions and identification of site of origin of metastatic tumors are frequent questions faced by pathologists. This chapter focuses on the application of immunohistochemical markers to these questions of hepatic and biliary tumor pathology. Staining profiles are presented for differentiating primary hepatocellular carcinomas, adenoma, and dysplastic nodules. Prognostic markers of hepatocellular adenoma subtypes are described. Challenges of distinguishing intrahepatic cholangiocarcinoma from metastatic mimics are addressed. A unique combination of complimentary markers useful in discriminating reactive from neoplastic epithelium in the gallbladder is shown. A process is defined utilizing an initial screening panel and subsequent confirmatory markers for unknown primary tumors in liver. Photomicrographs illustrate characteristic staining patterns.
References
Chu PG, Weiss LM. Modern immunohistochemistry. New York, NY: Cambridge University Press; 2009.
Dabbs DJ. Diagnostic immunohistochemistry. 3rd ed. Philadelphia, PA: Churchill Livingstone Elsevier; 2010.
Taylor C, Cote R. Immunomicroscopy a diagnostic tool for the surgical pathologist, Major problems in pathology. 3rd ed. Philadelphia, PA: Saunders Elsevier; 2006.
Geller SA, Dhall D, Alsabeh R. Application of immunohistochemistry to liver and gastrointestinal neoplasms: liver, stomach, colon, and pancreas. Arch Pathol Lab Med. 2008;132(3):490–9.
Mills SE. Histology for pathologists. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 696–7.
Burt AD, Portmann BC, Ferrell LD. MacSween’s pathology of the liver. 5th ed. Philadelphia: Churchill Livingstone Elsevier; 2007. p. 20–45.
De Young BR, Frierson Jr HF, Ly MN, Smith D, Swanson PE. CD31 immunoreactivity in carcinomas and mesotheliomas. Am J Clin Pathol. 1998;110(3):374–7.
de Boer WB, Segal A, Frost FA, Sterrett GF. Can CD34 discriminate between benign and malignant hepatocytic lesions in fine-needle aspirates and thin core biopsies? Cancer. 2000;90(5):273–8.
Gottschalk-Sabag S, Ron N, Glick T. Use of CD34 and factor VIII to diagnose hepatocellular carcinoma on fine needle aspirates. Acta Cytol. 1998;42(3):691–6.
Coston WM, Loera S, Lau SK, Ishizawa S, Jiang Z, Wu CL, et al. Distinction of hepatocellular carcinoma from benign hepatic mimickers using Glypican-3 and CD34 immunohistochemistry. Am J Surg Pathol. 2008;32(3):433–44.
Lin F, Shi J, Liu H, et al. Immunohistochemical detection of the von Hippel–Lindau gene product (pVHL) in human tissues and tumors: a useful marker for metastatic renal cell carcinoma and clear cell carcinoma of the ovary and uterus. Am J Clin Pathol. 2008;129(4):592–605.
Shah S, Gupta S, Shet T, Maheshwari A, Wuntkal R, Mohandas KM. Metastatic clear cell variant of hepatocellular carcinoma with an occult hepatic primary. Hepatobiliary Pancreat Dis Int. 2005;4(2):306–7.
Maeda T, Kajiyama K, Adachi E, Takenaka K, Sugimachi K, Tsuneyoshi M. The expression of cytokeratins 7, 19, and 20 in primary and metastatic carcinomas of the liver. Mod Pathol. 1996;9(9):901–9.
Rullier A, Le Bail B, Fawaz R, Blanc JF, Saric J, Bioulac-Sage P. Cytokeratin 7 and 20 expression in cholangiocarcinomas varies along the biliary tract but still differs from that in colorectal carcinoma metastasis. Am J Surg Pathol. 2000;24(6):870–6.
Harder J, Waiz O, Otto F, Geissler M, Olschewski M, Weinhold B, et al. EGFR and HER2 expression in advanced biliary tract cancer. World J Gastroenterol. 2009;15(36):4511–7.
Kandil DH, Cooper K. Glypican-3: a novel diagnostic marker for hepatocellular carcinoma and more. Adv Anat Pathol. 2009;16(2):125–9.
Shafizadeh N, Ferrell LD, Kakar S. Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum. Mod Pathol. 2008;21(8):1011–8. Epub 6 Jun 2008.
Wang HL, Anatelli F, Zhai QJ, Adley B, Chuang ST, Yang XJ. Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions. Arch Pathol Lab Med. 2008;132(11):1723–8.
Yamauchi N, Watanabe A, Hishinuma M, Ohashi K, Midorikawa Y, Morishita Y, et al. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol. 2005;18(12):1591–8.
Christensen WN, Boitnott JK, Kuhajda FP. Immunoperoxidase staining as a diagnostic aid for hepatocellular carcinoma. Mod Pathol. 1989;2(1):8–12.
Varma V, Cohen C. Immunohistochemical and molecular markers in the diagnosis of hepatocellular carcinoma. Adv Anat Pathol. 2004;11(5):239–49.
Haratake J, Hashimoto H. An immunohistochemical analysis of 13 cases with combined hepatocellular and cholangiocellular carcinoma. Liver. 1995;15(1):9–15.
Fanni D, Nemolato S, Ganga R, Senes G, Gerosa C, Van Eyken P, et al. Cytokeratin 20-positive hepatocellular carcinoma. Eur J Histochem. 2009;53(4):269–73.
Kakar S, Gown AM, Goodman ZD, Ferrell LD. Best practices in diagnostic immunohistochemistry: hepatocellular carcinoma versus metastatic neoplasms. Arch Pathol Lab Med. 2007;131(11):1648–54.
Krishna M. Diagnosis of metastatic neoplasms: an immunohistochemical approach. Arch Pathol Lab Med. 2010;134(2):207–15.
Lau SK, Prakash S, Geller SA, Alsabeh R. Comparative immunohistochemical profile of hepatocellular carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma. Hum Pathol. 2002;33(12):1175–81.
Wieczorek TJ, Pinkus JL, Glickman JN, Pinkus GS. Comparison of thyroid transcription factor-1 and hepatocyte antigen immunohistochemical analysis in the differential diagnosis of hepatocellular carcinoma, metastatic adenocarcinoma, renal cell carcinoma, and adrenal cortical carcinoma. Am J Clin Pathol. 2002;118:911–21.
Van Eyken P. Cytokeratin immunohistochemistry in liver histopatology. Adv Clin Pathol. 2000;4(4):201–11.
Zatloukal K, Stumptner C, Fuchsbichler A, Fickert P, Lackner C, Trauner M, et al. The keratin cytoskeleton in liver diseases. J Pathol. 2004;204(4):367–76.
Yang XR, Xu Y, Shi GM, Fan J, Zhou J, Ji Y, et al. Cytokeratin 10 and cytokeratin 19: predictive markers for poor prognosis in hepatocellular carcinoma patients after curative resection. Clin Cancer Res. 2008;14(12):3850–9.
Yong X-R, Xu Y, Shi G-M, Fan J, Zhou J, Ji Y, et al. Cytokeratin 10 and cytokeratin 19: predictive markers for poor prognosis in hepatocellular carcinoma patients after curative resection. Clin Cancer Res. 2008;14(12):3850–9.
Lackner C, Gogg-Kamerer M, Zatloukal K, Stumptner C, Brunt EM, Denk H. Ballooned hepatocytes in steatohepatitis: the value of keratin immunohistochemistry for diagnosis. J Hepatol. 2008;48(5):821–8. Epub 22 Feb 2008.
Lee MJ, Lee HS, Kim WH, Choi Y, Yang M. Expression of mucins and cytokeratins in primary carcinomas of the digestive system. Mod Pathol. 2003;16(5):403–10.
Listrom MB, Dalton LW. Comparison of keratin monoclonal antibodies MAK-6, AE1:AE3, and CAM-5.2. Am J Clin Pathol. 1987;88(3):297–301.
Jain R, Fischer S, Serra S, Chetty R. The use of cytokeratin 19 (CK19) immunohistochemistry in lesions of the pancreas, gastrointestinal tract, and liver. Appl Immunohistochem Mol Morphol. 2010;18(1):9–15.
Lefkowitch JH. Special stains in diagnostic liver pathology. Semin Diagn Pathol. 2006;23(3–4):190–8.
Fan Z, van de Rijn M, Montgomery K, Rouse RV. Hep par 1 antibody stain for the differential diagnosis of hepatocellular carcinoma: 676 tumors tested using tissue microarrays and conventional tissue sections. Mod Pathol. 2003;16(2):137–44.
Roskams T. The role of immunohistochemistry in diagnosis. Clin Liver Dis. 2002;6(2):571–89.
Morrison C, Marsh Jr W, Frankel WL. A comparison of CD10 to pCEA, MOC-31, and hepatocyte for the distinction of malignant tumors in the liver. Mod Pathol. 2002;15(12):1279–87.
Porcell AI, De Young BR, Proca DM, Frankel WL. Immunohistochemical analysis of hepatocellular and adenocarcinoma in the liver: MOC31 compares favorably with other putative markers. Mod Pathol. 2000;13(7):773–8.
Weinreb I, Cunningham KS, Perez-Ordoñez B, Hwang DM. CD10 is expressed in most epithelioid hemangioendotheliomas: a potential diagnostic pitfall. Arch Pathol Lab Med. 2009;133(12):1965–8.
Gu K, Shah V, Ma C, Zhang L, Yang M. Cytoplasmic immunoreactivity of thyroid transcription factor-1 (clone 8G7G3/1) in hepatocytes: true positivity or cross-reaction? Am J Clin Pathol. 2007;128(3):382–8.
Pan C-C, Chen PC-H, Tsay S-H, Chiang H. Cytoplasmic immunoreactivity for thyroid transcription factor-1 in hepatocellular Âcarcinoma. A comparative immunohistochemical analysis of four commercial antibodies using a tissue array technique. Am J Clin Pathol. 2004;121:343–9.
Batheja N, Suriawinata A, Saxena R, Ionescu G, Schwartz M, Thung SN. Expression of p53 and PCNA in cholangiocarcinoma and primary sclerosing cholangitis. Mod Pathol. 2000;13(12):1265–8.
Kanamoto M, Yoshizumi T, Ikegami T, Imura S, Morine Y, Ikemoto T, et al. Cholangiolocellular carcinoma containing hepatocellular carcinoma and cholangiocellular carcinoma, extremely rare tumor of the liver: a case report. J Med Invest. 2008;55(1–2):161–5.
Kang YK, Kim WH, Jang JJ. Expression of G1-S modulators (p53, p16, p27, cyclin D1, Rb) and Smad4/Dpc4 in intrahepatic cholangiocarcinoma. Hum Pathol. 2002;33(9):877–83.
Mosnier JF, Kandel C, Cazals-Hatem D, Bou-Hanna C, Gournay J, Jarry A, et al. N-cadherin serves as diagnostic biomarker in intrahepatic and perihilar cholangiocarcinomas. Mod Pathol. 2009;22(2):182–90. Epub 11 Jul 2008.
Nakanuma Y, Harada K, Ishikawa A, Zen Y, Sasaki M. Anatomic and molecular pathology of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg. 2003;10(4):265–81.
Rizzi PM, Ryder SD, Portmann B, Ramage JK, Naoumov NV, Williams R. p53 Protein overexpression in cholangiocarcinoma arising in primary sclerosing cholangitis. Gut. 1996;38(2):265–8.
Röcken C, Pross M, Brucks U, Ridwelski K, Roessner A. Cholangiocarcinoma occurring in a liver with multiple bile duct hamartomas (von Meyenburg complexes). Arch Pathol Lab Med. 2000;124(11):1704–6.
Nash JW, Morrison C, Frankel WL. The utility of estrogen receptor and progesterone receptor immunohistochemistry in the distinction of metastatic breast carcinoma from other tumors in the liver. Arch Pathol Lab Med. 2003;127(12):1591–5.
Esheba GE, Longacre TA, Atkins KA, Higgins JP. Expression of the urothelial differentiation markers GATA3 and placental S100 (S100P) in female genital tract transitional cell proliferations. Am J Surg Pathol. 2009;33(3):347–53.
Findeis-Hosey JJ, Yang Q, Spaulding BO, Wang HL, Xu H. IMP3 expression is correlated with histologic grade of lung adenocarcinoma. Human Pathol. 2010;41(4):477–84. Epub 11 Dec 2009.
Lu D, Vohra P, Chu PG, Woda B, Rock KL, Jiang Z. An oncofetal protein IMP3: a new molecular marker for the detection of esophageal adenocarcinoma and high-grade dysplasia. Am J Surg Pathol. 2009;33(4):521–5.
Werling RW, Yaziji H, Bacchi CE, Gown AM. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol. 2003;27(3):303–10.
Jarmay K, Gallai M, Karacsony G, et al. Decorin and actin expression and distribution in patients with chronic hepatitis C following interferon-alpha-2b-treatment. J Hepatol. 2000;32:993–1002.
Knittel T, Kobold D, Saile B, et al. Rat liver myofibroblasts and hepatic stellate cells: different cell populations of the fibroblast lineage with fibrogenic potential. Gastroenterology. 1999;117:1205–21.
Moreira RK. Hepatic stellate cells and liver fibrosis. Arch Pathol Lab Med. 2007;131(11):1728–34.
Okabe H, Beppu T, Hayashi H, Horino K, Masuda T, Komori H, et al. Hepatic stellate cells may relate to progression of intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2009;16(9):2555–64. Epub 23 Jun 2009.
Snover D. Immunohistochemical analysis in steatohepatitis: does it have a role in diagnosis and management? Am J Clin Pathol. 2005;123(4):491–3.
Svegliati Baroni G, D’Ambrosio L, Ferretti G, et al. Fibrogenic effect of oxidative stress on rat hepatic stellate cells. J Hepatol. 1999;30:868–75.
Tomanovic NR, Boricic IV, Brasanac DC, Stojsic ZM, Delic DS, Brmbolic BJ. Activated liver stellate cells in chronic viral C hepatitis: histopathological and immunohistochemical study. J Gastrointestin Liver Dis. 2009;18(2):163–7.
Bioulac-Sage P, Balabaud C, Bedossa P, et al. Pathological diagnosis of liver cell adenoma and focal nodular hyperplasia: Bordeaux update. J Hepatol. 2007;46:521–7.
Bioulac-Sage P, Balabaud C, Zucman-Rossi J. Subtype classification of hepatocellular adenoma. Dig Surg. 2010;27(1):39–45. Epub 1 Apr 2010.
Bioulac-Sage P, Blanc JF, Rebouissou S, Balabaud C, Zucman-Rossi J. Genotype phenotype classification of hepatocellular adenoma. World J Gastroenterol. 2007;13(19):2649–54.
Bioulac-Sage P, Laumonier H, Couchy G, Le Bail B, Sa Cunha A, Rullier A, et al. Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology. 2009;50(2):481–9.
Bioulac-Sage P, Laumonier H, Laurent C, Zucman-Rossi J, Balabaud C. Hepatocellular adenoma: what is new in 2008. Hepatol Int. 2008;2(3):316–21. Epub 1 May 2008.
Chen ZM, Crone KG, Watson MA, Pfeifer JD, Wang HL. Identification of a unique gene expression signature that differentiates hepatocellular adenoma from well-differentiated hepatocellular carcinoma. Am J Surg Pathol. 2005;29:1600–8.
Cohen C, Lawson D, DeRose PB. Sex and androgenic steroid receptor expression in hepatic adenomas. Human Pathology. 1998;29(12):1428–32.
Micchelli ST, Vivekanandan P, Boitnott JK, Pawlik TM, Choti MA, Torbenson M. Malignant transformation of hepatic adenomas. Mod Pathol. 2008;21:491–7.
Torbenson M, Lee JH, Choti M, et al. Hepatic adenomas: analysis of sex steroid receptor status and the Wnt signaling pathway. Mod Pathol. 2002;15(3):189–96.
Zucman-Rossi J, Jeannot E, Tran Van Nhieu J, et al. Genotype–phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology. 2006;43:515–24.
Ahmad I, Iyer A, Marginean CE, Yeh MM, Ferrell L, Qin L, et al. Diagnostic use of cytokeratins, CD34, and neuronal cell adhesion molecule staining in focal nodular hyperplasia and hepatic adenoma. Hum Pathol. 2009;40(5):726–34. Epub 20 Jan 2009.
Rebouissou S, Bioulac-Sage P, Zucman-Rossi J. Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma. J Hepatol. 2008;48(1):163–70.
Masood S, West AB, Barwick KW. Expression of steroid hormone receptors in benign hepatic tumors. An immunocytochemical study. Arch Pathol Lab Med. 1992;116(12):1355–9.
Yamamoto M, Nakajo S, Tahara E. Immunohistochemical analysis of estrogen receptors in human gallbladder. Acta Pathol Jpn. 1990;40(1):14–21.
Chen Ban K, Singh H, Krishnan R, Fong Seow H. Comparison of the expression of beta-catenin in hepatocellular carcinoma in areas with high and low levels of exposure to aflatoxin B1. J Surg Oncol. 2004;86(3):157–63.
Torbenson M, Kannangai R, Abraham S, Sahin F, Choti M, Wang J. Concurrent evaluation of p53, beta-catenin, and alpha-fetoprotein expression in human hepatocellular carcinoma. Am J Clin Pathol. 2004;122:377–82.
Peroukides S, Bravou V, Alexopoulos A, Varakis J, Kalofonos H, Papadaki H. Survivin overexpression in HCC and liver cirrhosis differentially correlates with p-STAT3 and E-cadherin. Histol Histopathol. 2010;25(3):299–307.
Malouf G, Falissard B, Azoulay D, Callea F, Ferrell LD, Goodman ZD, et al. Is histological diagnosis of primary liver carcinomas with fibrous stroma reproducible among experts? J Clin Pathol. 2009;62(6):519–24. Epub 20 Jan 2009.
Lau SK, Weiss LM, Chu PG. Differential expression of MUC1, MUC2, and MUC5AC in carcinomas of various sites: an immunohistochemical study. Am J Clin Pathol. 2004;122(1):61–9.
Cho MS, Lee SN, Sung SH, Han WS. Sarcomatoid hepatocellular carcinoma with hepatoblastoma-like features in an adult. Pathol Int. 2004;54(6):446–50.
Fu Y, Kobayashi S, Kushida Y, Saoo K, Haba R, Mori S, et al. Sarcomatoid hepatocellular carcinoma with chondroid variant: case report with immunohistochemical findings. Pathol Int. 2000;50(11):919–22.
Górnicka B, Ziarkiewicz-Wróblewska B, Wróblewski T, Wilczynski GM, Koperski L, Krawczyk M, et al. Carcinoma, a fibrolamellar variant–immunohistochemical analysis of 4 cases. Hepatogastroenterology. 2005;52(62):519–23.
Ward SC, Huang J, Tickoo SK, Thung SN, Ladanyi M, Klimstra DS. Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation. Mod Pathol. 2010;23(9):1180–90.
Abenoza P, Manivel JC, Wick MR, Hagen K, Dehner LP. Hepatoblastoma: an immunohistochemical and ultrastructural study. Hum Pathol. 1987;18(10):1025–35.
Cajaiba MM, Neves JI, Casarotti FF, de Camargo B, ChapChap P, Sredni ST, et al. Hepatoblastomas and liver development: a study of cytokeratin immunoexpression in twenty-nine hepatoblastomas. Pediatr Dev Pathol. 2006;9(3):196–202.
López-Terrada D, Gunaratne PH, Adesina AM, Pulliam J, Hoang DM, Nguyen Y, et al. Histologic subtypes of hepatoblastoma are characterized by differential canonical Wnt and Notch pathway activation in DLK+ precursors. Hum Pathol. 2009;40(6):783–94. Epub 5 Feb 2009.
Stocker JT. Hepatoblastoma. Semin Diagn Pathol. 1994;11(2):136–43.
Warfel KA, Hull MT. Hepatoblastomas: an ultrastructural and immunohistochemical study. Ultrastruct Pathol. 1992;16(4):451–61.
Ushiku T, Shinozaki A, Shibhara J, et al. SALL4 represents fetal gut differentiation of gastric cancer, and is diagnostically useful in distinguishing hepatoid gastric carcinoma from hepatocellular carcinoma. Am J Surg Pathol. 2010;34:533–40.
Machado I, Noguera R, Santonja N, Donat J, Fernandez-Delgado R, Acevedo A, et al. Immunohistochemical study as a tool in differential diagnosis of pediatric malignant rhabdoid tumor. Appl Immunohistochem Mol Morphol. 2010;18(2):150–8.
Lin F, Liu H, Shi J, Xu Y, Zhang J, Wang HL. Diagnostic utility of von Hipple–Lindau gene product (pVHL) and S100P in adenocarcinoma and dysplasia of the gallbladder. Abstract presentation in CAP 2009.
Lin F, Shi J, Wang HL, Liu H. Diagnostic utility of von Hipple–Lindau gene product (pVHL), maspin, KOC, and S100P in adenocarcinoma of the gallbladder. Accepted for poster presentation in the coming USCAP meeting, 2010 in Washington, DC.
Nagata S et al. Co-expression of gastric and biliary. Oncol Rep. 2007;17:721–9.
Shibahara H et al. Pathologic features of mucin. Am J Surg Pathol. 2004;28:327–38.
Yang GC, Yang GY, Tao LC. Distinguishing well-differentiated hepatocellular carcinoma from benign liver by the physical features of fine-needle aspirates. Mod Pathol. 2004;17(7):798–802.
Terracciano LM, Glatz K, Mhawech P, et al. Hepatoid adenocarcinoma with liver metastasis mimicking hepatocellular carcinoma. Am J Surg Pathol. 2003;27:1302–12.
Di Tommaso L, Destro A, Seok JY, Balladore E, Terracciano L, Sangiovanni A, et al. The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. J Hepatol. 2009;50(4):746–54. Epub 25 Dec 2008.
Di Tommaso L, Franchi G, Park YN, Fiamengo B, Destro A, Morenghi E, et al. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology. 2007;45(3):725–34.
Hytiroglou P, Theise ND. Differential diagnosis of hepatocellular nodular lesions. Semin Diagn Pathol. 1998;15(4):285–99.
Libbrecht L, Severi T, Cassiman D, et al. Glycipan-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules. Am J Surg Pathol. 2006;30:1405–11.
Roskams T, Kojiro M. Pathology of early hepatocellular carcinoma: conventional and molecular diagnosis. Semin Liver Dis. 2010;30(1):17–25. Epub 19 Feb 2010.
Hornick JL, Fletcher CD. PEComa: what do we know so far? Histopathology. 2006;48(1):75–82.
Tryggvason G, Blöndal S, Goldin RD, Albrechtsen J, Björnsson J, Jónasson JG. Epithelioid angiomyolipoma of the liver: case report and review of the literature. APMIS. 2004;112(9):612–6.
Chu PG, Schwarz RE, Lau SK, Yen Y, Weiss LM. Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2. Am J Surg Pathol. 2005;29(3):359–67.
Hruban RH, Pitman MB, Klimstra DS. AFIP Atlast of Tumor Pathology, Tumors of the Pancreas, vol. 4. 6th ed. Washington, DC: American Registry of Pathology; 2007.
Levy M, Lin F, Xu H, Dhall D, Spaulding BO, Wang HL. S100P, von Hippel-Lindau gene product, and IMP3 serve as a useful immunohistochemical panel in the diagnosis of adenocarcinoma on endoscopic bile duct biopsy. Hum Pathol. 2010;41(9):1210–9.
Lin F, Shi J, Liu H, et al. Diagnostic utility of S100P and von Hippel–Lindau gene product (pVHL) in pancreatic adenocarcinoma – with implication of their roles in early tumorigenesis. Am J Surg Pathol. 2008;32(1):78–91.
Zhou H, Schaefer N, Wolff M, Fischer HP. Carcinoma of the ampulla of Vater: comparative histologic/immunohistochemical classification and follow-up. Am J Surg Pathol. 2004;28(7):875–82.
Yesim G, Gupse T, Zafer U, Ahmet A. Mesenchymal hamartoma of the liver in adulthood: immunohistochemical profiles, clinical and histopathological features in two patients. J Hepatobiliary Pancreat Surg. 2005;12(6):502–7.
Doi H, Horiike N, Hiraoka A, Koizumi Y, Yamamoto Y, Hasebe A, et al. Primary hepatic marginal zone B cell lymphoma of mucosa-associated lymphoma of mucosa-associated lymphoid tissue type: case report and review of the literature. Int J Hematol. 2008;88:418–23. Epub 23 Sep 2008.
Anagnostopoulos G, Sakorafas GH, Grigoriadis K, Kostopoulos P. Malignant fibrous histiocytoma of the liver: a case report and review of the literature. Mt Sinai J Med. 2005;72(1):50–2.
Fujita S, Lauwers GY. Primary hepatic malignant fibrous histiocytoma: report of a case and review of the literature. Pathol Int. 1998;48(3):225–9.
Yuri T, Danbara N, Shikata N, Fujimoto S, Nakano T, Sakaida N, et al. Malignant rhabdoid tumor of the liver: case report and literature review. Pathol Int. 2004;54(8):623–9.
Guglielmi A, Frameglia M, Iuzzolino P, Martignoni G, De Manzoni G, Laterza E, et al. Solitary fibrous tumor of the liver with CD 34 positivity and hypoglycemia. J Hepatobiliary Pancreat Surg. 1998;5(2):212–6.
Zhang MF, Zhang ZY, Fu J, Yang YF, Yun JP. Correlation between expression of p53, p21/WAF1, and MDM2 proteins and their prognostic significance in primary hepatocellular carcinoma. J Transl Med. 2009;22(7):110.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Prichard, J., Lin, F. (2011). Liver, Bile Ducts, and Gallbladder. In: Lin, F., Prichard, J. (eds) Handbook of Practical Immunohistochemistry. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-8062-5_23
Download citation
DOI: https://doi.org/10.1007/978-1-4419-8062-5_23
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-8061-8
Online ISBN: 978-1-4419-8062-5
eBook Packages: MedicineMedicine (R0)